WuXi Biologics (Cayman) Inc.

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:42 28/06/2024 BST			5-day change	1st Jan Change
11.54 ^HKD	-1.20%		-1.54%	-61.01%

06-27	Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	MT
06-19	Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	MT

WuXi Biologics Inc. Elects Mr. Kenneth Walton Hitchner III as Independent Non-Executive Director

June 09, 2020 at 03:56 pm

WuXi Biologics (Cayman) Inc. announced that its shareholders elected Mr. Kenneth Walton Hitchner III as independent non-executive Director.

Latest news about WuXi Biologics (Cayman) Inc.

Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	06-27	MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	06-19	MT
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban	06-13	MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	06-01	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	05-31	RE
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains	05-27	RE
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	05-17	MT
US House committee advances bill to restrict BGI, WuXi AppTec	05-15	RE
US House committee to vote on bill to restrict BGI, WuXi AppTec	05-15	RE
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	05-14	MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	05-13	DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	05-10	RE
Pacific Assets Trust cautiously optimistic after outpacing benchmark	04-30	AN
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	04-01	CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	03-27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	03-27	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	03-19	MT
WuXi AppTec's Shares Fall After Downbeat Guidance	03-19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	03-19	DJ
WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700	03-17	CI
WuXi Biologics Inc.(SEHK:2269) dropped from S&P Global 1200	03-17	CI
Hong Kong Shares Drop as PBoC Keeps Key Policy Rate Unchanged	03-15	MT
WuXi Shares Fall as Washington Lobbying Group Cuts Ties	03-14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE

Chart WuXi Biologics (Cayman) Inc.

Duration

Period

More charts

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

18/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.74 CNY

Average target price

21.06 CNY

Spread / Average Target

+96.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI BIOLOGICS (CAYMAN) INC.	-61.01%	6.21B
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	122B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.86%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.90%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.52B

Bio Therapeutic Drugs

WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

WuXi Biologics Inc. Elects Mr. Kenneth Walton Hitchner III as Independent Non-Executive Director

Latest news about WuXi Biologics (Cayman) Inc.

Chart WuXi Biologics (Cayman) Inc.

Company Profile

Income Statement Evolution

Ratings for WuXi Biologics (Cayman) Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs